Roche Forecast, price target & analysts
Roche Target price 2025 - Analyst rating & recommendation
Roche Classifications & Recommendation:
Roche Price Target
| Target Price | CHF307.52 |
| Price | CHF298.40 |
| Potential | 3.06% |
| Number of Estimates | 21 |
| 21 Analysts have issued a price target Roche 2026 . The average Roche target price is CHF307.52. This is 3.06% higher than the current stock price. The highest price target is CHF448.00 50.13% , the lowest is CHF230.00 22.92% . | |
| A rating was issued by 25 analysts: 11 Analysts recommend Roche to buy, 10 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Roche stock has an average upside potential 2026 of 3.06% . Most analysts recommend the Roche stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion CHF | 60.50 | 64.96 |
| 3.03% | 7.38% | |
| EBITDA Margin | 35.81% | 39.48% |
| 6.07% | 10.25% | |
| Net Margin | 13.66% | 23.25% |
| 29.92% | 70.19% |
20 Analysts have issued a sales forecast Roche 2025 . The average Roche sales estimate is CHF65.0b . This is 7.38% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF67.3b 11.27% , the lowest is CHF63.4b 4.84% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | CHF60.5b | 3.03% |
|---|---|---|
| 2025 | CHF65.0b | 7.38% |
| 2026 | CHF67.9b | 4.54% |
| 2027 | CHF70.6b | 3.96% |
| 2028 | CHF73.0b | 3.38% |
| 2029 | CHF75.2b | 3.01% |
18 Analysts have issued an Roche EBITDA forecast 2025. The average Roche EBITDA estimate is CHF25.6b . This is 21.90% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF27.5b 30.57% , the lowest is CHF23.0b 9.39% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | CHF21.7b | 9.28% |
|---|---|---|
| 2025 | CHF25.6b | 18.38% |
| 2026 | CHF27.1b | 5.53% |
| 2027 | CHF28.0b | 3.48% |
| 2028 | CHF29.7b | 6.09% |
EBITDA Margin
| 2024 | 35.81% | 6.07% |
|---|---|---|
| 2025 | 39.48% | 10.25% |
| 2026 | 39.85% | 0.94% |
| 2027 | 39.67% | 0.45% |
| 2028 | 40.71% | 2.62% |
14 Roche Analysts have issued a net profit forecast 2025. The average Roche net profit estimate is CHF15.1b . This is 82.77% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF17.0b 105.34% , the lowest is CHF12.6b 52.84% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | CHF8.3b | 27.80% |
|---|---|---|
| 2025 | CHF15.1b | 82.77% |
| 2026 | CHF16.3b | 7.98% |
| 2027 | CHF17.0b | 4.45% |
| 2028 | CHF18.4b | 8.26% |
| 2029 | CHF19.4b | 5.17% |
Net Margin
| 2024 | 13.66% | 29.92% |
|---|---|---|
| 2025 | 23.25% | 70.19% |
| 2026 | 24.02% | 3.31% |
| 2027 | 24.13% | 0.46% |
| 2028 | 25.27% | 4.72% |
| 2029 | 25.80% | 2.10% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 10.39 | 18.99 |
| 27.80% | 82.77% | |
| P/E | 15.71 | |
| EV/Sales | 4.01 |
14 Analysts have issued a Roche forecast for earnings per share. The average Roche <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is CHF18.99 . This is 82.77% higher than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is CHF21.33 105.29% , the lowest is CHF15.88 52.84% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | CHF10.39 | 27.80% |
|---|---|---|
| 2025 | CHF18.99 | 82.77% |
| 2026 | CHF20.50 | 7.95% |
| 2027 | CHF21.42 | 4.49% |
| 2028 | CHF23.19 | 8.26% |
| 2029 | CHF24.39 | 5.17% |
P/E ratio
| Current | 28.72 | 81.31% |
|---|---|---|
| 2025 | 15.71 | 45.30% |
| 2026 | 14.55 | 7.38% |
| 2027 | 13.93 | 4.26% |
| 2028 | 12.87 | 7.61% |
| 2029 | 12.24 | 4.90% |
Based on analysts' sales estimates for 2025, the Roche stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 4.01 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 3.65 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 4.31 | 22.79% |
|---|---|---|
| 2025 | 4.01 | 6.86% |
| 2026 | 3.84 | 4.34% |
| 2027 | 3.69 | 3.80% |
| 2028 | 3.57 | 3.27% |
| 2029 | 3.47 | 2.92% |
P/S ratio
| Current | 3.92 | 26.62% |
|---|---|---|
| 2025 | 3.65 | 6.87% |
| 2026 | 3.50 | 4.34% |
| 2027 | 3.36 | 3.81% |
| 2028 | 3.25 | 3.27% |
| 2029 | 3.16 | 2.92% |
Current Roche Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG | Hold ➜ Hold | Unchanged | Jan 06 2025 |
| BNP PARIBAS EXANE | Outperform ➜ Outperform | Unchanged | Dec 08 2024 |
| HSBC | Buy ➜ Buy | Unchanged | Nov 24 2024 |
| TD COWEN | Hold ➜ Hold | Unchanged | Nov 19 2024 |
| REDBURN ATLANTIC | Buy ➜ Buy | Unchanged | Nov 03 2024 |
| DZ BANK | Buy ➜ Buy | Unchanged | Oct 24 2024 |
| LANDESBANK BADEN-WUERTTEMBERG | Buy ➜ Buy | Unchanged | Oct 23 2024 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
BERENBERG: Hold ➜ Hold
|
Jan 06 2025 |
|
Unchanged
BNP PARIBAS EXANE: Outperform ➜ Outperform
|
Dec 08 2024 |
|
Unchanged
HSBC: Buy ➜ Buy
|
Nov 24 2024 |
|
Unchanged
TD COWEN: Hold ➜ Hold
|
Nov 19 2024 |
|
Unchanged
REDBURN ATLANTIC: Buy ➜ Buy
|
Nov 03 2024 |
|
Unchanged
DZ BANK: Buy ➜ Buy
|
Oct 24 2024 |
|
Unchanged
LANDESBANK BADEN-WUERTTEMBERG: Buy ➜ Buy
|
Oct 23 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
